Table 3.
a. Tumor Characteristics.
| Total population | Younger group | Older group | p-value | N | |
|---|---|---|---|---|---|
| Morphology | 1.000 | 77 | |||
| Multicentric | 32 (41.6%) | 25 (41.0%) | 7 (43.8%) | ||
| Multifocal | 45 (58.4%) | 36 (59.0%) | 9 (56.2%) | ||
| Tumor size | 20.0 [3.50;130] | 18.0 [3.50;130] | 25.0 [6.00;120] | <0.001 | 325 |
| Nodal status | 0.400 | 315 | |||
| Negative | 189 (58.7%) | 149 (57.3%) | 40 (64.5%) | ||
| Positive | 133 (41.3%) | 111 (42.7%) | 22 (35.5%) | ||
| cT stage | 0.274 | 148 | |||
| 0 | 1 (0.68%) | 1 (0.83%) | 0 (0.00%) | ||
| 1 | 70 (47.3%) | 62 (50.4%) | 8 (32%) | ||
| 2 | 69 (46.6%) | 53 (43.1%) | 16 (64%) | ||
| 3 | 8 (5.41%) | 7 (5.69%) | 1 (4.00%) | ||
| cN stage | 0.057 | 144 | |||
| 0 | 116 (80.6%) | 99 (82.5%) | 17 (70.8%) | ||
| 1 | 25 (17.4%) | 20 (16.7%) | 5 (20.8%) | ||
| 1(i) | 1 (0.69%) | 0 (0.00%) | 1 (4.17%) | ||
| 2 | 1 (0.69%) | 0 (0.00%) | 1 (4.17%) | ||
| 2b | 1 (0.69%) | 1 (0.83%) | 0 (0.00%) | ||
| Number of cN | 0.028 | 120 | |||
| 0 | 92 (76.7%) | 80 (79.2%) | 12 (63.2%) | ||
| 1 | 26 (21.7%) | 21 (20.8%) | 5 4 (26.3%) | ||
| 2 | 2 (1.67%) | 0 (0.00%) | 2 (10.5%) | ||
| Staging | 0.039 | 326 | |||
| IA | 110 (33.7%) | 94 (35.7%) | 16 (25.4%) | ||
| IB | 5 (1.53%) | 5 (1.90%) | 0 (0.00%) | ||
| IIA | 121 (37.1%) | 97 (36.9%) | 24 (38.1%) | ||
| IIB | 67 (20.6%) | 51 (19.4%) | 16 (25.4%) | ||
| IIIA | 15 (4.60%) | 13 (4.94%) | 2 (3.17%) | ||
| IIIB | 2 (0.61%) | 1 (0.38%) | 1 (1.59%) | ||
| IIIC | 4 (1.23%) | 2 (0.76%) | 2 (3.17%) | ||
| IV | 2 (0.61%) | 0 (0.00%) | 2 (3.17%) | ||
| pT | <0.001 | 326 | |||
| 1 | 174 (53.4%) | 154 (58.6%) | 20 (31.7%) | ||
| 2 | 121 (37.1%) | 88 (33.5%) | 33 (52.4%) | ||
| 3 | 29 (8.90%) | 20 (7.60%) | 9 (14.3%) | ||
| 4 | 2 (0.61%) | 1 (0.38%) | 1 (1.59%) | ||
| pN | 0.132 | 324 | |||
| 0 | 188 (58%) | 148 (56.3%) | 40 (65.6%) | ||
| 1 | 127 (39.2%) | 108 (41.1%) | 19 (31.1%) | ||
| 2 | 5 (1.54%) | 5 (1.90%) | 0 (0.00%) | ||
| 3 | 4 (1.23%) | 2 (0.76%) | 2 (3.28%) | ||
| Nodal excision | 0.033 | 137 | |||
| SLN | 96 (70.1%) | 86 (74.1%) | 10 (47.6%) | ||
| SLN+Axilla | 23 (16.8%) | 16 (13.8%) | 7 (33.3%) | ||
| Axilla | 18 (13.1%) | 14 (12.1%) | 4 (19%) |
Table 3a: shows the different clinical-pathological factor in the older and younger group. ER=estrogen receptor, PR = progesterone receptor, SLN = Sentinel lymph node biopsy.